Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
antigen, attenuator, Calypso, celiac, circulating, consumption, costimulatory, DC, differentiate, disability, eosinophilic, inflamed, inhibitory, lymphocyte, migration, modality, molecule, NK, periphery, preferentially, primed, proven, repayment, rocatinlimab
Removed:
collective, dysregulation, Merck, myeloid, Pandion, remained, worked
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view